Citius Pharmaceuticals Inc
CTXRW
NASDAQ Capital Market0.14
USD
-0.01
- -
CIK
0001506251
Return %
Stock
S&P500
1Y
- -
26.84
3Y
-42.34
77.03
5Y
-44.81
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- None
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- NV United States of America
- IPO Date
- Aug 3, 2017
- CIK
- 0001506251
- Similar Companies
- Business
- Citius Pharmaceuticals Inc (Nasdaq: CTXR; CTXRW) is a late-stage biopharmaceutical company that develops and commercializes first-in-class critical care products, including anti-infectives for adjunct cancer care, oncology therapies, stem cell treatments and unique prescription products; its FDA-approved LYMPHIR (denileukin diftitox-cxdl) targets relapsed or refractory cutaneous T-cell lymphoma in adults following at least one prior systemic therapy; the late-stage pipeline features Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related or central line-associated bloodstream infections where it met primary and secondary endpoints in a pivotal Phase 3 trial completed in 2023; Halo-Lido (CITI-002), a proprietary topical formulation of halobetasol propionate and lidocaine for anti-inflammatory and anesthetic relief of hemorrhoids following a Phase 2b trial completed in 2023; and NoveCite mesenchymal stem cells for acute respiratory distress syndrome and other conditions. The company, founded in 2007 and headquartered in Cranford, New Jersey, operates primarily in the US with global sales potential for select assets targeting hospitals, oncologists, critical care specialists and patients with underserved needs in oncology and infection control. Recent developments include the August 2024 FDA approval of LYMPHIR and the completion of a merger spinning off its oncology subsidiary with TenX Keane Acquisition Corp to form Citius Oncology Inc (Nasdaq: CTOR), in which Citius retains an approximately 84-90% stake to focus commercialization efforts including a planned US launch in Q4 2025 supported by an exclusive agreement with EVERSANA and international distribution expansion to Turkey and the Middle East; a $6.0 million registered direct offering in October 2025 and a $3.0 million offering in January 2025 to fund LYMPHIR launch milestones, manufacturing, regulatory activities and pipeline advancement; ongoing FDA engagement for Mino-Lok and Halo-Lido next steps; and promising preliminary Phase 1 results for LYMPHIR combined with pembrolizumab in recurrent solid tumors.